AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03296358
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 2 groups would receive IV Dexamethasone in ED and Oral prednisolone as home medication.
Trial: NCT01942122
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control will be mefenamic acid 500 mg tablets, administered 3 times daily for 5 days during the menstrual period, i.e. day 1st to day 5th of the menstrual period. The drug will be given within the 8 weeks of study period (2 menstrual cycles).
Trial: NCT01942122
Drug: DLBS1442 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study treatment will be DLBS1442 capsules at a dose of 3x200 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
Trial: NCT02125435
Drug: ASP2408
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous
Trial: NCT02125435
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous
Trial: NCT02112916
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00345696
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2, orally, every 12 hours, continuous.
Trial: NCT00348764
Drug: lauromacrogol
RxNorm normalized name: Lauromacrogol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03707587
Drug: M7824
RxNorm normalized name: M7824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 1200 mg intravenous (IV) of M7824 on day 1 of a 14 day cycle, every other week, for up to 12 weeks total treatment (6 cycles).
Trial: NCT02112916
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02112916
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02112916
Drug: Hydrocortisone Sodium Succinate
RxNorm normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IT
Trial: NCT02112916
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO or IV
Trial: NCT02112916
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Give PO
Trial: NCT02112916
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT, IV, or PO
Trial: NCT01537887
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally once daily for 10 days.
Trial: NCT02105272
Drug: OPC-1085EL ophthalmic solution
RxNorm normalized name: Opcon-A Ophthalmic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00935571
Drug: propofol, remifentanil, sevoflurane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol: using target controlled infusion (TCI); 1-3ug/ml remifentanil: using TCI by 5-20 ng/ml sevoflurane: 2-3volume% (1-2 MAC)
Trial: NCT02294591
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on treatment of placebo
Trial: NCT02590367
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX regimens are combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (different dose like FOLFOX4/FOLFOX6) via ambulatory pump administered for a period of 46 to 48 hours.~XELOX is a combination therapy of Oxaliplatin 130mg/ m\^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m\^2 bid, days 1-14, every 3 weeks.
Trial: NCT02590367
Drug: HD6610 Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the HD6610 Granule will be given 2 times a day.
Trial: NCT02590367
Drug: HD6610 Granule placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the HD6610 Granule placebo will be given 2 times a day.
Trial: NCT01989000
Drug: [F-18]HX4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 MBq \[F-18\]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
Trial: NCT03767322
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will receive before and after coronary intervention
Trial: NCT00133471
Drug: MF59 adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59 adjuvant is an oil-in-water emulsion.
Trial: NCT03425747
Drug: Calcium Citrate
RxNorm normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subjects will be assigned to a calcium supplement (Carbonate or Citrate) at the same total amount of elemental calcium that they had taken before the study enrolment.
Trial: NCT00074152
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given within 10 weeks after surgery.
Trial: NCT01116583
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperatively (2 hours before surgery): 4 placebo capsules~Postoperative day 1: 1 placebo capsule x 2~Postoperative day 2: 1 placebo capsule x 3~Postoperative day 3: 1 placebo capsule x 4~Postoperative day 4: 1 placebo capsule x 4~Postoperative day 5: 1 placebo capsule x 4
Trial: NCT02801383
Drug: Yallaferon®， the recombinant human interferon α-2b gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01604941
Drug: SPD602
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg/day orally twice daily for 24 weeks
Trial: NCT01926236
Drug: 5 FU
RxNorm normalized name: i5 Functional Food Nutritional Powder for Suspension (Vanilla Delight)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 FU 400 mg/m2 (bolus), 2400 mg/m2 (infusion), q 14d, up to 12 cycles
Trial: NCT02111564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients, randomly allocated to the placebo arm, will receive one placebo tablet with or without food.
Trial: NCT03930732
Drug: Inhaled Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation
Trial: NCT03930732
Drug: Inhaled Long-Acting Beta Agonist
RxNorm normalized name: Sinex Long-Acting Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation
Trial: NCT03930732
Drug: Inhaled Long-Acting Muscarinic Antagonist
RxNorm normalized name: Sinex Long-Acting Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation
Trial: NCT03930732
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Trial: NCT01356550
Drug: RO4917838
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT02354703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + BBCET counseling
Trial: NCT01968460
Drug: P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed Dose Combination of pramipexole 0.6 mg and rasagiline 0.75 mg once daily
Trial: NCT01968460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01968460
Drug: P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed Dose Combination of pramipexole 0.3 mg and rasagiline 0.75 mg once daily
Trial: NCT00397722
Drug: GW876008
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04363372
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules will be identical in appearance to active product.
Trial: NCT02893358
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corresponding placebo once daily taken in the morning during 8:00-9:00. Duration: 12 months.
Trial: NCT01548001
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2.5 mg/tablet, taken orally once a week, 4 tablets/week (week 1-week 4) , 6 tablets/week (week 5- week 52)
Trial: NCT01693315
Drug: AMA0076
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01923545
Drug: PEG-G-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vial, 3.6mg/day or 6mg/day, single dosing per cycle, for 1 cycle
Trial: NCT01410227
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syringe supplied with physiologic saline solution for infusion
Trial: NCT01693315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02063139
Drug: Flutiform 50/5 ug (2 puffs bid) pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04471922
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose, 1 tablet QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
Trial: NCT04322344
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antiviral drugs
Trial: NCT00098917
Drug: autologous tumor cell vaccine
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00098917
Drug: therapeutic autologous dendritic cells
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04537663
Drug: Bacille Calmette-Guérin (BCG)
RxNorm normalized name: BACILLUS CALMETTE-GUERIN,TICE VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the intervention group will be vaccinated with the licensed BCG vaccine (Danish strain 1331, SSI, Denmark) using the standard vaccination technique for this vaccine (intradermal injection in the left upper arm).
Trial: NCT02170662
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04133961
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion 0.3ml/kg/hour (normal saline in 20ml syringe)
Trial: NCT04537663
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection of sterile 0.9% NaCl.
Trial: NCT02284035
Drug: EFV/TDF/FTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard combination therapy
Trial: NCT02284035
Drug: ATV/r + TDF/FTC or DRV/r + TDF/FTC
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02599961
Drug: UX007
RxNorm normalized name: UX007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UX007 is a liquid intended for oral (PO) administration.
Trial: NCT05055193
Drug: Evaluation at 24 months corrected age: respiratory outcome, Neurodevelopmental outcome, Growth outcome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data concerning the 24 months corrected age outcomes were collected from the medical records of the ECL'AUR preterm infants follow-up network.
Trial: NCT02284035
Drug: DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02284035
Drug: EFV plus ABC/3TC or RPV/TDF/FTC
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02284035
Drug: ATV/r plus ABC/3TC
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02284035
Drug: DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04592783
Drug: Antihypertensive Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive medications will be initialed once BP is at predetermined threshold
Trial: NCT02284035
Drug: RAL plus ABC/3TC
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01362205
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive placebo (normal saline)
Trial: NCT02284035
Drug: Other ART regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03174483
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nasal spray
Trial: NCT02164422
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01100944
Drug: PXD101with cisplatin+doxorubicin+cyclophosphamide
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PXD101 will be given as a 48h continuous intravenous infusion (CIVI) starting on day 1, doxorubicin as a slow intravenous (IV) injection on days 2 and 3, cisplatin will be infused over 1 hour on day 2 and cyclophosphamide as a slow IV infusion on Day 3. Treatment will be given every 21 days for no more than 6 cycles or until disease progression. Treatment with PXD101 alone may continue until disease progression.
Trial: NCT02853643
Drug: ASN002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose study with food effect
Trial: NCT00139698
Drug: olmesartan alone or in combination with hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / olmesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01172431
Drug: Indapamide
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide SR 1.5mg qd
Trial: NCT03714490
Drug: CAPOX
RxNorm normalized name: Capecitabine and Oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive consolidation chemotherapy after 7-10 days of SCPRT completed, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are scheduled before surgery.
Trial: NCT01808651
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03423342
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo capsule
Trial: NCT00279305
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous infusion
Trial: NCT01405742
Drug: rF.VIII
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 IU/kg recombinant factor VIII will be given once-weekly or thrice-weekly by intravenous injection for 26 weeks. At 26 weeks after a 72 hour washout period, 40 IU/kg recombinant factor VIII will be given thrice-weekly or once-weekly, respectively, by intravenous injection until week 52, with up to two rescue doses per week for bleeds
Trial: NCT01997879
Drug: AR-13324 Ophthalmic Solution, 0.02%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eyedrop
Trial: NCT01014832
Drug: Intensive insulin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy
Trial: NCT00608985
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem
Trial: NCT00718952
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
Trial: NCT02160574
Drug: 0.9% Physiological Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The degree of skin irritation caused by 0.9% Physiological Saline will be graded and compared to ZuraPrep and ZuraPrep without IPA.
Trial: NCT03491371
Drug: Methylsulfonic apatinib
RxNorm normalized name: 3,4-methylenedioxybenzoyl methylsulfone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-angiogenesis Tyrosine kinase inhibitor which specifically inhibits VEGFR-2.
Trial: NCT04063930
Drug: LOKELMA 5 GM Powder for Oral Suspension
RxNorm normalized name: Lokelma 5 GM Powder for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium zirconium cyclosilicate (a hyperkalemia treatment)
Trial: NCT04063930
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT03200860
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo, 10 mg daily, oral, 30 days
Trial: NCT03429946
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive spironolactone 12 hours and 3 hours before the initiation of the hyperinsulinemic clamp treatment.
Trial: NCT03429946
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo 12 hours and 3 hours before the initiation of the hyperinsulinemic clamp treatment.
Trial: NCT04342897
Drug: LY3127804
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT04342897
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT03440268
Drug: N Acetyl Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrate NAC in the pre operatory and intra operatory moments and assess the influence in the outcomes
Trial: NCT03440268
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These participants will receive a saline solution in pre operatory with the same volume as the experimental group, and this solution will be administrated in 2 hours. During the surgery they will receive a new solution with the same volume of the experimental group, and this solution will be administrated in 6 hours too. The solutions will be covered by an opaque bag, so the participant will not see what is being administrated
Trial: NCT00684515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets; once daily for 60 days
Trial: NCT04225715
Drug: CpAM (RO7049389)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CpAM (RO7049389) will be administered orally
Trial: NCT01934205
Drug: GSK2140944 (Single dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously as a single dose.
Trial: NCT04123899
Drug: IGAD→GSTD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: IGAD First Period: Single oral administration of 1 tablet of Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug)~Other: Washout period 7 days~Drug: GSTD Second Period: Single oral administration of 1 tablet of Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)
Trial: NCT00738595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match EVT 302, 5 mg
Trial: NCT01119417
Drug: Bq123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose day: 100 nmol/min, single IV infusion for 15 min.
Trial: NCT00130598
Drug: NaCl 0.9% i.v. or NaBic 1.4% i.v. or NaBic 1.4% i.v. + NaBic p.o. (Nephrotrans®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control group: preventive hydration with 154mEq/l saline at 1ml/kg per hour of 12 hours prior and after the procedure.~7h-sodium bicarbonate: before contrast 3ml/kg NaHCO3 166mEq/l for one hour, followed by NaHCO3 166mEq/l (1ml/kg per hour until 6h after contrast).~short-term sodium bicarbonate: NaHCO3 166mEq/l (3ml/kg) as a bolus 20 minutes before contrast; ingestion of Nephrotrans® (500mg NaHCO3/capsule: 1 capsule/10kg) with 1-2 dl non-sparkling mineral water at the start of the infusion. Ingestion of non-sparkling mineral water in the first 6 hours after contrast.
Trial: NCT02574637
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching Brazikumab IV infusion as per protocol specified dosing schedule.
Trial: NCT00859703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 35 mg once a week for 24 months
Trial: NCT00835614
Drug: CEFZIL® for Oral Suspension 250 mg/5mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 250 mg/5 mL, single-dose fasting
Trial: NCT03434769
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 60mg/Kg on day -6
Trial: NCT00006479
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006479
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006479
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00985439
Drug: Diclofenac Test (upper dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35-mg Single dose
Trial: NCT00985439
Drug: Celecoxib 400 mg
RxNorm normalized name: celecoxib 400 MG
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules 2 x 200 mg Single-dose